Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023)

Contineum Therapeutics (CTNM) has 1 years of Long-Term Debt Repayments data on record, last reported at $3.1 million in Q2 2023.

  • For Q2 2023, Long-Term Debt Repayments changed N/A year-over-year to $3.1 million; the TTM value through Mar 2024 reached $3.1 million, changed N/A, while the annual FY2023 figure was $3.8 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $3.1 million in Q2 2023 per CTNM's latest filing, up from $625000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $3.1 million in Q2 2023 and bottomed at $625000.0 in Q1 2023.